Effects of Acarbose on Endothelial Function After a Mixed Meal in Newly Diagnosed Type 2 Diabetes
- Registration Number
- NCT00551954
- Lead Sponsor
- Technische Universität Dresden
- Brief Summary
Endothelial dysfunction (ED) has been suggested as a possible causal link between postprandial hyperglycemia and cardiovascular events in patients with type 2 diabetes. Recent trials demonstrated a reduction of cardiovascular events by treatment with the alpha glucosidase inhibitor acarbose - a drug which mainly reduces postprandial glucose excursions. We were interested whether patients with newly diagnosed type 2 diabetes showed postprandial ED and if so whether acarbose was able to improve this condition.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- age 35-75 years
- type 2 diabetes (newly diagnosed)
- well glycemic control (HbA1c </= 8.1)
- leucocyte count > 6.2 or hs CrP > 1
Exclusion Criteria
- hs CrP > 10
- type 1 diabetes
- previous treatment with antidiabetic drugs
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 1 acarbose 20 weeks of treatment with acarbose (100 mg t.i.d.) 2 placebo 20 weeks of treatment with placebo (one tablet t.i.d.)
- Primary Outcome Measures
Name Time Method forearm blood flow assessed by forearm occlusion plethysmography after a mixed meal at baseline and after 20 weeks of treatment
- Secondary Outcome Measures
Name Time Method forearm blood flow assessed by forearm occlusion plethysmography in the fasting state, plasma glucose excursion in response to the mixed meal, insulin levels in response to the mixed meal, triglyceride levels in response to the mixed meal at baseline and after 20 weeks of treatment